Business Wire

iProov Now Providing Facial Authentication for NHS Login Across Android and iOS

Share

iProov, the world leader in spoof-resistant, biometric authentication technology, today announced that its technology has been deployed to verify users signing up to NHS login across Android and iOS. Following an initial launch on Android, iProov’s technology is now available on the iOS version of the NHS App.

This enables users in England to create their NHS login remotely, securely and conveniently at a time when they need it most, removing the need for manual and in-person verifications. The NHS App allows for easy and fast access to essential services such as GP appointments, access to medical records and ordering repeat prescriptions.

iProov’s Flashmark facial verification technology is now used by users to create an NHS login through the NHS App. Once a user submits a photo of their identity document, such as a valid passport or driving licence, they will be prompted to position their face correctly on the screen. Following a short sequence of flashing colours, the user’s identification will be verified and they will be able to access all the information and services the NHS App has to offer, following completion of all other checks including matching a user to their medical record.

The iProov process verifies that an individual is a real person, the right person, and is authenticating themselves right now. This protects against the risk of identity theft while giving people quicker and more convenient access to vital services wherever they are. It also frees up valuable NHS resources and saves money, as NHS Digital now needs to process far fewer manual applications. More than a million people have now registered with NHS login, with a peak of over 60,000 new IDs verified during the first week of April. The combined iProov and NHS solution has proven its ability to cope with an unprecedented increase in demand.

Andrew Bud, Founder and CEO, iProov said: “The NHS login service is now a proven, secure, inclusive and effective way for citizens to verify and use their identity for health-related purposes. We have been very impressed by what the NHS Digital team has accomplished, by their agility and professionalism, and by the boldness of their vision.

“This is particularly important in the current climate in which demand is unprecedented and the need for convenient and robust remote identity verification is crucial. We are delighted to be playing our part.”

Melissa Ruscoe, Programme Head for NHS login, said: “iOS users are now able to benefit from faster automatic identity verification when creating their NHS login, giving them a single safe and secure way to access their digital healthcare services such as the NHS App.

“Over the past couple of months we have seen a surge in demand in people registering for an NHS login as they look to manage their health digitally.

“More automated tools like this will help us to improve the experience of our users, increase demand capacity and ensure nobody is waiting too long to complete identity verification checks to gain access to their digital healthcare services.”

In addition to NHS login, iProov’s unique patented technology is used to verify identities in the Home Office ‘EU Exit: ID Document Check’ app which enables European citizens to apply to the EU Settlement Scheme. iProov also provides governments, banks and other enterprises with Genuine Presence Assurance, including the US Department for Homeland Security, allowing them to authenticate users remotely on smartphones or other devices.

ENDS

About iProov
Founded in 2011, iProov is a world leader in spoof-resistant, biometric facial authentication technology. Its technology is used by banks and governments around the world for secure customer onboarding, logon and authentication, to ensure new and returning users are genuine, and to guard against fraudulent attempts to gain access to personal data. For more information, see www.iproov.com.

About NHS login
NHS login is a service that has been created by the NHS for patients and the public. It provides a re-usable way for patients to access multiple digital health and social care services with a single login, which includes authentication for returning users.

NHS login can be used by the public to securely access their health and care information wherever they see the NHS login button. People can use NHS login to prove who they are safely and securely and, in most cases, without the need to visit their GP.

Contact information

PR contacts
Tyto
Lauren Armour
lauren.armour@tytopr.com
+44 203 026 000

NHS Digital
Tom Donnelly
Thomas.donnelly@nhs.net
07864 690124

About Business Wire

Business Wire
Business Wire



Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Spirit of Wipro Run Brings Together Thousands of Participants Globally27.9.2020 08:52:00 CESTPress release

Wipro Limited (NYSE: WIT, BSE: 507685, NSE: WIPRO), a leading global information technology, consulting and business process services company, today organized the 15th edition of the ‘Spirit of Wipro’ (SOW) Run globally with thousands of participants across 35 countries, running separately, yet together in spirit, at a time of their choosing. The theme for this year’s Run was “United. Unstoppable”, which celebrated camaraderie, resilience and a shared sense of community among several thousands of Wipro employees, their friends and families, alumni, customers, partners and suppliers. The SOW Run is an annual, global tradition at Wipro and has been held every year since its inception. This year too, the Run was organized on schedule despite the pandemic induced constraints. The runners strictly adhered to the local COVID-19 guidelines and safety protocols in various countries while participating in the event. Commenting on the Run, Thierry Delaporte, Chief Executive Officer and Managing

BCG Collaborates with Tencent Marketing Insight to Release 2020 BCG x Tencent Digital Luxury Report25.9.2020 12:21:00 CESTPress release

Since early 2020 when the COVID-19 pandemic broke out worldwide, the luxury market has been hit hard and is expected to decline 25% to 45% compared to the previous year. The Chinese luxury market, however, which has benefitted from successful domestic control of the pandemic and has taken the lead in recovery against a depressed global market environment, is forecast to grow from 20% to 30% in the whole year of 2020. Thanks to its stunning market performance, China has become the main battleground of each major luxury brand. In was in this environment that Boston Consulting Group (BCG) joined hands with Tencent Marketing Insight (TMI) to release the 2020 BCG x Tencent Digital Luxury Report, drawing on deep insights into post COVID-19 trends in the luxury market and consumers based on BCG and TMI’s quantitative consumer research and industry experience, as well as TMI’s marketing and big data capabilities. Crystal Hao, Managing Director & Partner of BCG said, “The luxury market in China

U.S. MRTP Authorization Pathway Explored in PMI’s Latest Scientific Update25.9.2020 12:15:00 CESTPress release

Philip Morris International (PMI) (NYSE: PM) has released the 11th edition of its Scientific Update, a regularly issued publication on its research efforts to develop and scientifically assess a range of smoke-free alternatives to cigarettes. The latest edition features an overview of the historic decision made by the U.S. Food and Drug Administration (FDA) to authorize the marketing of the IQOS Tobacco Heating System with reduced exposure information. The Scientific Update explains the various MRTP decisions under U.S. law; the steps, processes, and timeline PMI undertook; and the ongoing post-market surveillance and studies that will monitor the impact of the orders on consumer perceptions, behavior, and health. “The FDA undertook a scientific and regulatory evaluation of IQOS and determined that it is ‘appropriate for the promotion of public health’” said Dr. Gizelle Baker, director of Global Scientific Engagement at PMI. “In this edition of our Scientific Update, we describe how th

Palladio Completes $20 Million Series B Financing25.9.2020 12:09:00 CESTPress release

Palladio Biosciences, Inc. (Palladio), a privately-held, clinical stage biopharmaceutical company developing medicines for orphan diseases of the kidney, announced today the completion of a $20 million Series B investment. The financing was led by new investor, Samsara BioCapital, with participation from new investor, the Roche Venture Fund and existing investors, Medicxi and Osage University Partners. Proceeds from the financing will fund Palladio’s Phase 3 ALERT Study and advance operations. Srinivas Akkaraju M.D, Ph.D, Managing General Partner of Samsara BioCapital, stated, "We are very excited about our investment in Palladio to support the development of lixivaptan, a drug that has the potential to deliver a meaningful therapeutic advancement in the treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD). The ALERT Study is an important step in assessing the safety differential of lixivaptan.” “We are very pleased that Samsara and the Roche Venture Fund recognize the opp

Ant Group Launches “Trusple,” an AntChain-Powered Global Trade and Financial Services Platform for SMEs and Financial Institutions25.9.2020 09:54:00 CESTPress release

Ant Group, a leading provider in the development of open platforms for technology-driven inclusive financial services, and the parent company of China’s largest digital payment platform Alipay, today unveiled Trusple, an international trade and financial service platform powered by AntChain, the company’s blockchain-based technology solutions. Trusple aims to make it easier and less costly for all participants – especially Small-to-Medium Enterprises (SMEs) – to sell their products and services to customers around the world. It also reduces costs for financial institutions so they can better serve SMEs in need. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200925005110/en/ (Photo: Business Wire) Based on the concept of “Trust Made Simple,” Trusple works by generating a smart contract once a buyer and a seller upload a trading order on the platform. As the order is executed, the smart contract is automatically updated with k

Ipsen Appoints Philippe Lopes-Fernandes as Executive Vice President, Chief Business Officer25.9.2020 07:00:00 CESTPress release

Regulatory News: This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200924005822/en/ Philippe Lopes-Fernandes, Executive Vice President, Chief Business Officer, Ipsen (Photo: Business Wire) Ipsen (Euronext: IPN; ADR: IPSEY) today announced the appointment of Philippe Lopes-Fernandes as Executive Vice President, Chief Business Officer, effective 1 October 2020. Based in Cambridge, Massachusetts, USA, he will be responsible for business development and alliance management, reporting directly to David Loew, CEO, Ipsen. Philippe will serve on the Executive Leadership Team. “As Chief Business Officer, Philippe will play a crucial role in our external innovation strategy. The ELT and I are delighted to welcome Philippe to Ipsen and look forward to working closely with him. His extensive and impressive track record in international business development, his outstanding reputation and his ability to work closely with the scientific comm

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom